Man Group PLC Altimmune, Inc. Transaction History

Man Group PLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$2.4 - $3.45 $60,000 - $86,250	25,000 Added 76.4%	57,723 $150,000
Q2 2023 Aug 14, 2023	SELL	$3.45 - $5.97 $18,050 - $31,235	-5,232 Reduced 13.78%	32,723 $115,000
Q1 2023 May 15, 2023	BUY	$4.19 - $16.83 $107,804 - $433,019	25,729 Added 210.44%	37,955 $160,000
Q4 2022 Feb 14, 2023	BUY	$8.74 - $16.45 $106,855 - $201,117	12,226 New	12,226 $201,000
Q4 2020 Feb 16, 2021	SELL	$7.84 - $14.22 $128,576 - $233,208	-16,400 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$9.93 - $33.26 $162,852 - $545,464	16,400 New	16,400 $216,000

208

39.5M

1.94M

1.38M

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $315M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.